Ocata Therapeutics Receives New U.S. Patent for Its RPE Therapy for Macular Degenerative Diseases
July 15 2015 - 08:00AM
Business Wire
New Patent Strengthens Ocata’s Proprietary
Position of its RPE Manufacturing Process from All Pluripotent Stem
Cell Sources
Ocata Therapeutics, Inc. (NASDAQ:OCAT), a leader in the field of
Regenerative Ophthalmology™, today announced that it continues to
fortify the patent protection covering its retinal pigment
epithelium (RPE) transplant technology for macular degeneration
with the issuance by the United States Patent and Trademark Office
(USPTO) of U.S. Patent No 9,080,150.
“The issuance of this 9th U.S. patent in our global RPE
portfolio represents yet another example of the leadership position
we have established as pioneers in Regenerative Ophthalmology,”
said Paul K. Wotton, Ph.D., President and Chief Executive Officer.
“In particular, this new patent provides coverage for the
manufacture of all RPE products from any pluripotent source by
defining the basic universal markers of RPE essential for
therapeutic use. We have recently received patent
protection for the manufacture of human RPE cell products from
pluripotent stem cell sources, including manufacture of formulation
forms for use as therapeutic agents as well as the use of these RPE
formulations for treating degenerative ophthalmic diseases, such as
dry age-related macular degeneration (dry AMD) and Stargardt’s
macular degeneration (SMD).”
About Ocata Therapeutics, Inc.
Ocata Therapeutics, Inc. is a clinical stage biotechnology
company focused on the development and commercialization of
Regenerative Ophthalmology therapeutics. Ocata’s most advanced
products are in clinical trials for the treatment of Stargardt’s
macular degeneration, dry age-related macular degeneration, and
myopic macular degeneration. Ocata’s intellectual property
portfolio includes pluripotent stem cell platforms – hESC and
induced pluripotent stem cell (iPSC) – and other cell therapy
research programs. For more information, visit www.ocata.com.
About Age-related Macular Degeneration
Age-related macular degeneration is the leading cause of vision
loss in people over the age of 50. Every year in the USA there are
1.8 million patients newly diagnosed with dry AMD which occurs when
light-sensitive photoreceptor cells in the macula, located in the
center of the retina, slowly break down, causing vision loss as a
result. Photoreceptor breakdown is a consequence of loss or damage
to the RPE layer. As the disease progresses, patients may have
difficulty reading and recognizing faces. There is currently no
proven medical therapy for dry AMD and the projected number of
people worldwide with age-related macular degeneration in 2020 is
196 million, increasing to 288 million in 2040, underscoring the
urgent need for new treatments.
About Stargardt’s Disease
Stargardt’s macular degeneration is a form of juvenile macular
degeneration that affects vision in children and young adults
between the ages of six and 20, with a prevalence of approximately
one in 10,000 people in the United States. It is an orphan disease
and loss of vision is an inevitable aspect of SMD, with more than
half of the patients experiencing vision loss in the range of
20/200-20/400. Like dry AMD, it occurs as a result of damage to the
RPE layer and there are no treatments currently approved to prevent
or slow the vision loss associated with SMD.
Forward-Looking Statements
All statements, other than historical facts, contained in this
news release, including statements regarding Ocata’s beliefs
regarding the enhanced protection provided by its new and existing
patents, the effect of such patents on the Company’s development
plans and its belief that it has a leadership position in the field
of regenerative ophthalmology, and any other statements about
Ocata’s future expectations, beliefs, goals, plans, results or
prospects expressed by management constitute forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Any statements that are not statements of
historical fact (including statements containing the words “will,”
“believes,” “plans,” “anticipates,” “expects,” “estimates,” and
similar expressions) should also be considered to be
forward-looking statements. There are a number of important factors
that could cause actual results or events to differ materially from
those indicated by such forward-looking statements, including: the
fact that Ocata has no product revenue and no products approved for
marketing; Ocata’s limited operating history; Ocata’s need for and
limited sources of future capital; potential failures or delays in
obtaining regulatory approval of products; risks inherent in the
development and commercialization of potential products; reliance
on new and unproven technology in the development of products; the
need to protect Ocata’s intellectual property; the challenges
associated with conducting and enrolling clinical trials; the risk
that the results of clinical trials may not support Ocata’s product
candidate claims; the risk that physicians and patients may not
accept or use Ocata’s products, even if approved; Ocata’s reliance
on third parties to conduct its clinical trials and to formulate
and manufacture its product candidates; and economic conditions
generally. Additional information on potential factors that could
affect our results and other risks and uncertainties are detailed
from time to time in Ocata’s periodic reports, including the Annual
Report on Form 10-K for the fiscal year ended December 31, 2014.
Forward-looking statements are based on the beliefs, opinions, and
expectations of Ocata’s management at the time they are made, and
Ocata does not assume any obligation to update its forward-looking
statements if those beliefs, opinions, expectations, or other
circumstances should change. Forward-looking statements are based
on the beliefs, opinions, and expectations of Ocata’s management at
the time they are made, and Ocata does not assume any obligation to
update its forward-looking statements if those beliefs, opinions,
expectations, or other circumstances should change. There can be no
assurance that Ocata’s future clinical trials will be successful or
that the results of previous clinical studies will lead to
commercialization or products or therapies.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150715005410/en/
For Ocata Therapeutics, Inc.Investors:Westwicke PartnersJohn
Woolford, 443-213-0506john.woolford@westwicke.comorPress:Russo
PartnersDavid Schull,
858-717-2310david.schull@russopartnersllc.com
Ocata Therapeutics, Inc. (NASDAQ:OCAT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Ocata Therapeutics, Inc. (NASDAQ:OCAT)
Historical Stock Chart
From Mar 2023 to Mar 2024